Leptomeningeal Metastasis Diagnosis and Treatment Strategies

Leptomeningeal metastasis arises when malignant cells infiltrate the arachnoid and pia mater, leading to diffuse involvement of the cerebrospinal fluid pathways and neural surfaces. Clinical presentation is heterogeneous, encompassing headache, cranial neuropathies, seizures and spinal symptoms. Diagnostic work-up combines high-resolution contrast-enhanced MRI with cerebrospinal fluid cytology, immunocytochemistry and emerging molecular assays to improve sensitivity. Key challenges include low tumour cell yield in CSF and difficulty distinguishing treatment effects from active disease. Standard treatment modalities comprise intrathecal chemotherapy, systemic targeted agents and focal radiotherapy, often tailored to the primary tumour’s molecular profile. Recent advances have introduced immunotherapies and small-molecule inhibitors delivered both systemically and directly into the CSF. Despite these innovations, overall survival remains measured in months, underscoring the need for earlier detection, rational combination regimens and more effective strategies to overcome microenvironment-mediated resistance.

Research from Nature Portfolio

Phase 1 data on combined intrathecal and intravenous administration of an anti-PD-1 antibody have established a safe dosing regimen and documented preliminary signs of efficacy in patients with leptomeningeal involvement from melanoma and lung cancer. Delivery directly into the CSF achieved adequate central nervous system exposure without dose-limiting toxicities, and survival outcomes at six months surpassed historical expectations for similar cohorts. Concurrent systemic infusion appeared to augment central antitumour immunity and may mitigate peripheral tumour escape.

Comprehensive genomic profiling of breast cancer leptomeningeal metastases using cell-free DNA and disseminated tumour cells in CSF has revealed a distinctive lobular-like phenotype characterised by aberrations in adherens junction and cytoskeletal genes. Patient-derived organoids and in vivo models established from CSF cells have highlighted unique dependencies amenable to targeted interventions. This work underscores the value of liquid biopsy approaches for uncovering actionable mutations and biological vulnerabilities in hard-to-access tumour deposits.

Leptomeningeal Metastasis Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in leptomeningeal metastasis diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Leptomeninges: The two inner membranes (arachnoid and pia mater) that envelop the brain and spinal cord.

Intrathecal: Administration of drugs directly into the cerebrospinal fluid space surrounding the central nervous system.

Cerebrospinal fluid (CSF): Clear fluid that circulates in the subarachnoid space and ventricles, providing mechanical support and a medium for biomarker analysis.

Cell-free DNA (cfDNA): Fragmented DNA released into body fluids by apoptotic or necrotic cells, used as a minimally invasive tumour biomarker.

Organoids: Three-dimensional cell culture systems that recapitulate key structural and functional aspects of the original tumour.

Spatial transcriptomics: A technology that maps gene expression within intact tissue sections to reveal the spatial organisation of cellular phenotypes.

Immune checkpoint inhibitors: Therapeutic antibodies that block regulatory pathways in T cells to enhance antitumour immune responses.

References

1. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nature Medicine (2023).
2. Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nature Communications (2023).
3. Pharmacotherapy for leptomeningeal disease in breast cancer. Cancer Treatment Reviews (2023).
4. Spatial transcriptomics analysis identifies a tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease. Cell Reports Medicine (2024).
5. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget (2017).